Business
BioMarin Announces Record Fourth Quarter and Full Year 2022 Total Revenues Driven by Strong Global Demand for VOXZOGO® and Steady Growth of Enzyme Business
VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 BillionIn 2023, More than 15% Growth in Total Revenues and Approximately
About this update from Biomarin Pharmaceutical Inc.
[{"type":"text","content":"VOXZOGO $169 Million Contribution Drives Record Full Year 2022 Total Revenues of $2.1 BillionIn 2023, More than 15% Growth in Total Revenues and Approximately 30% Growth in Net Income Expected Based on Mid-point of Today's Full-year Guidance; VOXZOGO Revenues Expected to More than DoubleROCTAVIAN European Commercial Launch and U.S. Launch Preparations Both Underway; 3-year Analysis from Phase 3 ROCTAVIAN Study in Adults with Severe Hemophilia A Recently Submitted to the FDAFinancial Highlights (in millions of U.S. dollars, except per share data, unaudited)\nThree Months Ended\nDecember 31,\nTwelve Months Ended\nDecember 31,\n2022\n2021\n% Change\n2022\n2021\n% Change\nTotal Revenues\n$ 537.5\n$ 449.8\n19 %\n$ 2,096.0\n$ 1,846.3\n14 %\nNet Product Revenues Marketed by BioMarin (1)\n$ 487.9\n$ 414.9\n18 %\n$ 1,913.6\n$ 1,660.7\n15 %\nVIMIZIM® Net Product Revenues\n$ 152.1\n$ 156.3\n(3) %\n$ 663.8\n$ 623.1\n7 %\nNAGLAZYME® Net Product Revenues\n$ 100.5\n$ 83.1\n21 %\n$ 443.8\n$ 380.4\n17 %\nPALYNZIQ® Net Product Revenues\n$ 72.3\n$ 63.8\n13 %\n$ 255.0\n$ 237.5\n7 %\nVOXZOGO Net Product Revenues\n$ 66.8\n$ 5.8\n1,052 %\n$ 169.1\n$ 5.9\n2,766 %\nKUVAN® Net Product Revenues\n$ 53.6\n$ 68.5\n(22) %\n$ 227.6\n$ 285.8\n(20) %\nBRINEURA® Net Product Revenues\n$ 42.6\n$ 37.4\n14 %\n$ 154.3\n$ 128.0\n21 %\nALDURAZYME® Net Product Revenues\n$ 37.6\n$ 20.3\n85 %\n$ 128.4\n$ 122.8\n5 %\nGAAP Net Income (Loss)\n$ (0.2)\n$ (57.9)\n$ 141.6\n$ (64.1)\nGAAP Earnings (Loss) per Share – Basic\n$ (0.00)\n$ (0.32)\n$ 0.76\n$ (0.35)\nGAAP Earnings (Loss) per Share – Diluted\n$ (0.00)\n$ (0.32)\n$ 0.75\n$ (0.35)\nNon-GAAP Income (2)\n$ 67.4\n$ 7.1\n$ 364.6\n$ 242.8\nDecember 31,2022\nDecember 31,2021\nTotal cash, cash equivalents & investments\n$ 1,625.4\n$ 1,521.7\n(1)\nNet Product Revenues Marketed by BioMarin is the sum of revenues from VIMIZIM, NAGLAZYME, PALYNZIQ, KUVAN, VOXZOGO and BRINEURA for the three and twelve months ended December 31, 2022 and 2021, each calculated in accordance with Generally Accepted Accounting Principles in the United States (U.S. GAAP). Sanofi is BioMarin's sole customer for ALDURAZYME and is responsible for marketing and selling ALDURAZYME to third parties.\n(2)\nNon-GAAP Income for the historical periods presented is defined by the Company as reported GAAP Net Income/Loss, excluding net interest income (expense), provis...